CliffBio
biologic

Letybo

letibotulinumtoxinA-wlbg

Loss of exclusivityFebruary 2036projected — 12-year biologic exclusivity estimate
CompanyHugel →View the full company profile on CliffBio

Drug detail

Brand nameLetybo
Active ingredientletibotulinumtoxinA-wlbg
Strength50UNITS
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2024
Marketing statusRx

More from Hugel

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Letybo patent cliff — loss of exclusivity February 2036 | CliffBio